Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ultrasound zaps a new brain spot to quiet Parkinson's tremors

NCT ID NCT06259708

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether low-intensity focused ultrasound aimed at a brain area called the zona incerta (ZI) can reduce tremors in 20 people with Parkinson's disease. Researchers compared this approach to the standard target (Vim) and used brain scans to understand how the treatment works. The goal is to find a better way to control tremors without surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low intensity focused ultrasound (device)
What this could lead to
If successful, this could point toward a more effective brain target for ultrasound treatment of Parkinson's tremor.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply to everyone. The treatment is still experimental and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Mar 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of Parkinson's disease * Resting tremor score (MDS-UPDRS III 3.17 Rest Tremore Amplitude (RUE or LUE)) ≥ 2 * Between the ages of 40-80 years * Hoehn and Yahr stage between 1-3 (mild to moderate PD) in the "ON" state * Patients who are willing to have a partial (\~8 cm diameter circular area above the ear) hair shaving. Exclusion Criteria: * Atypical Parkinsonism * History of essential tremor * Dementia preventing informed consent * Change in Parkinson's medication with the last 2 weeks * Neurological disease other than PD, including Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, a brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma * Unstable medical conditions or serious disease/conditions (e.g., cancer undergoing active treatment, poorly controlled diabetes) * Concurrent treatment for PD with Duodopa * Concurrent treatment for PD with deep brain stimulation (DBS) * Thickness of the temporal bone \< 7 mm * Individuals should also not participate if they have any of the following contraindications for undergoing fMRI scanning: * Cardiac pacemaker, wires, or defibrillator * Metal in eye or orbit, including the history of any eye injury involving metal fragments and increased risk due to (history of) working as a metal worker (grinding, machining, or welding) * Ferromagnetic aneurysm clip * Possibility of pregnancy * Artificial heart valve * Ear or eye implant, including cochlear implant * Brain aneurysm clip * Implanted drug infusion pump * Electrical stimulator to nerves or bones * Coil, catheter, or filter in any blood vessel * Orthopedic hardware (artificial joint, plate, screw, rod) * Other metallic prostheses * Shrapnel, bullets, or other metal fragments * Surgery, piercings or tattoos (including tattooed eyeliner) in the last six weeks * Medication releasing skin patches (i.e. nicotine, birth control, nitroglycerine) * History of claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of British Columbia, DMCBH

    Vancouver, British Columbia, V6T 1Z3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.